Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
ALN-CIDEB in Metabolic Dysfunction Associated Steatohepatitis: NCT06836609 Clinical Landscape Report 2026
18 September 2026
NCT06836609 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
GS1191-0445 in Hemophilia A: NCT06833983 Clinical Landscape Report 2026
18 September 2026
NCT06833983 clinical landscape for Hemophilia A: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Niacin in Fibrosis, Liver: NCT06843148 Clinical Landscape Report 2026
18 September 2026
NCT06843148 clinical landscape for Fibrosis, Liver: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Freeze-dried Concentrated Human Blood Coagulation Factor IX(Japan Blood Products Organization) in Hemophilia B: CTRI/2025/03/081608 Clinical Landscape Report 2026
18 September 2026
CTRI/2025/03/081608 clinical landscape for Hemophilia B: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Recombinant Human Coagulation Factor VIII (Takeda) in Hemophilia A: NCT06864975 Clinical Landscape Report 2026
18 September 2026
NCT06864975 clinical landscape for Hemophilia A: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fludarabine Phosphate in Red blood cell disorder: NCT06872333 Clinical Landscape Report 2026
18 September 2026
NCT06872333 clinical landscape for Red blood cell disorder: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
XENON XE 129 hyperpolarized in Idiopathic Pulmonary Fibrosis: NCT06853145 Clinical Landscape Report 2026
18 September 2026
NCT06853145 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
NNC0581-0001 in Metabolic Dysfunction Associated Steatohepatitis: NCT06891365 Clinical Landscape Report 2026
18 September 2026
NCT06891365 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Afimkibart in Metabolic Dysfunction Associated Steatohepatitis: NCT06903065 Clinical Landscape Report 2026
18 September 2026
NCT06903065 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Efgartigimod Alfa in Myasthenia Gravis: NCT06909214 Clinical Landscape Report 2026
18 September 2026
NCT06909214 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tebapivat in Hemoglobin SC Disease: NCT06924970 Clinical Landscape Report 2026
18 September 2026
NCT06924970 clinical landscape for Hemoglobin SC Disease: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Cannabidiol in Pain: NCT06930703 Clinical Landscape Report 2026
18 September 2026
NCT06930703 clinical landscape for Pain: endpoints, sponsor, phase, geography, readouts, asset context and development white space.